arrow
Ò

Òscar Reig

university of barcelona
H指数:23
被引数:1,886

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Non-Cancer Causes of Death in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Analysis

转移性激素敏感性前列腺癌患者的非癌性死亡原因:一项真实世界分析

2026-05-010
OAAI
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

ctDNA指导下的辅助阿特珠单抗治疗在肌肉浸润性膀胱癌中的应用

2025-10-0110
PRE
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study

卡博替尼治疗晚期肾细胞癌在西班牙和葡萄牙真实世界实践中的有效性与安全性:SOGUG-SPRWEC研究

2025-09-010
PRE
Pharmacokinetics and Bioavailability of Pembrolizumab With Berahyaluronidase Alfa for Subcutaneous Administration in Participants With Advanced or Metastatic Solid Tumors: The Phase 1 Study 3475A-C18

帕博利珠单抗联合重组人透明质酸酶α皮下给药的药代动力学与生物利用度研究:晚期或转移性实体瘤患者I期研究3475A-C18

2025-08-090
PREAI
Corrigendum to “Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors” [Eur. Urol. Open Sci. 70 (2024) 86–90]

勘误:“接受雄激素受体通路抑制剂治疗的有转移性激素敏感性前列腺癌患者中RB1、PTEN和TP53基因的预后表达特征”[Eur. Urol. Open Sci. 70 (2024) 86–90]

2025-06-040
OA
Corrigendum to “Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients” [Eur. Urol. Oncol. 7 (2024) 954–964]

勘误:关于“基于RB1、PTEN和TP53在转移性激素敏感性前列腺癌患者中开发并独立验证预后基因表达签名”[Eur. Urol. Oncol. 7 (2024) 954–964]

2025-05-010
PRE
Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors

雄激素受体途径抑制剂治疗的转移性激素敏感型前列腺癌患者RB1、PTEN和TP53基因的预后表达特征

2024-12-011
PRE
Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors

接受自行车毒素偶联物(BTCs)BT8009或BT5528单药治疗的晚期实体瘤患者中出现的周围神经病变(PN)。

2024-09-011
PRE
BT8009 monotherapy in enfortumab vedotin (EV)-naive patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1

BT8009单药治疗在enfotumab vedotin(EV)初治患者(pts)中的转移性尿路上皮癌(mUC):Duravelo-1研究的更新结果

2024-09-012
PRE
Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients

肿瘤抑制基因特征可预测转移性激素敏感性前列腺癌(mHSPC)患者的早期进展

2024-09-010
PRE
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients
2024-08-014
OA
Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesis
2024-02-224
OAAI
Molecular profiling and prognostic relevance of low PTEN expression in metastatic hormone-sensitive prostate cancer patients
2023-10-010
PRE
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
2022-10-265
OA
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

在一线醋酸阿比曲酮或恩扎鲁他胺治疗无症状骨转移的转移性去势抵抗性前列腺癌患者的镭223: 一项单臂II期试验

2022-09-017
PRE
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
2022-04-0112
OAAI
A renal cell carcinoma tumorgraft platform to advance precision medicine
2021-11-0123
OAAI